肝病治療藥物市場按治療類型、分銷管道和地區：2023-2030 年市場規模、份額、前景、機會分析

Liver Diseases Therapeutics Market, Therapy Type, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: 2023年07月25日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

肝臟是人體最大的器官。它的功能是消化食物、儲存能量、排除毒素。肝臟疾病有多種類型，包括由甲型、B型、C型肝炎等病毒引起的肝臟疾病，以及因過量攝取藥物、毒物和酒精引起的肝臟疾病。例子包括脂肪肝和肝硬化。活癌也是一種數量不斷增加的疾病。還有幾種影響肝臟的遺傳性疾病，例如血色素沉著症和威爾森氏症。影響肝臟的疾病的常見症狀包括腹部或腿部腫脹、容易瘀青、黃疸以及糞便或尿液顏色的變化。影像學檢查和肝功能檢查可用於檢查肝損傷和診斷肝病。肝病的治療包括抗排斥藥物/免疫抑制劑、化療藥物、標靶治療、疫苗、抗病毒藥物、免疫球蛋白和皮質類固醇。

市場動態

肝病市場的發展、新療法的研發以及肝病治療的監管批准正在推動全球肝病藥物市場的成長。例如，2022年5月26日，美國製藥公司Pfizer公司宣布，美國食品藥物管理局已批准Pfizer公司的在研藥物聯合療法作為與肝纖維化相關的非酒精性脂肪性肝炎（NASH）的治療方法。已被指定軌道。快速通道是一個旨在加速新藥和疫苗的開發和審查的過程，旨在治療和預防嚴重疾病並解決未滿足的醫療需求。合併治療的兩種藥物是ervogastat和clesacostat。該決定是基於Pfizer非臨床和 2a 期臨床試驗中該藥物積極的安全性和耐受性，以及肝臟脂肪的減少。

本次考試的主要特色

本報告對全球肝病治療藥物市場進行了詳細分析，並提出了以2022年為基準年的預測期（2023-2030年）的市場規模和復合年增長率（CAGR）。
它也揭示了各個細分市場的潛在收入機會，並為該市場提供了一系列有吸引力的投資建議。
它還提供了有關市場驅動因素、限制因素、機會、新產品發布和批准、市場趨勢、區域前景、主要參與者採取的競爭策略等的重要見解。
根據公司亮點、產品組合、主要亮點、績效和策略等參數對全球肝病治療藥物市場的主要公司進行了分析。
本研究涵蓋的主要公司包括Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
此報告的見解使行銷人員和公司高層能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
《全球肝病治療藥物市場報告》是針對該產業的各個利害關係人，例如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球肝病治療藥物市場的各種策略矩陣，將有助於利害關係人做出決策。

北美
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地區
歐洲
英國
德國
義大利
法國
西班牙
俄羅斯
歐洲其他地區
亞太地區
中國
印度
日本
東協
澳大利亞
韓國
其他亞太地區
中東
海灣合作委員會
以色列
其他中東地區
非洲
北非
中非
南非

第八章競爭態勢

Astellas Pharma Inc.
Bristol-Myers Squibb.
Gilead Sciences
Glaxosmithkline Plc
Hoffmann-La Roche Ltd
Merck & Co.
Novartis AG
Sanofi S.A
Pfizer Inc.
Takeda Pharmaceuticals
Valeant Pharmaceuticals
Watson Pharmaceuticals, Inc.
Theratechnologies Inc.
Alnylam Pharmaceuticals, Inc.
Protagonist Therapeutics, Inc.
Dicerna Pharmaceuticals, Inc.
Endo International
Provectus Biopharmaceuticals Inc.
MAX BioPharma, Inc.

第 9 章

調查方法
關於出版商

簡介目錄

Product Code: CMI3809

Liver is the largest organ of the human body. It helps to digest food, store energy, and remove poisons. There are many kinds of liver diseases like diseases caused by viruses such as hepatitis A, hepatitis B, and hepatitis C. Diseases can also be caused by drugs, poisons, or too much alcohol consumption. Examples include fatty liver disease and cirrhosis. Live cancer is another growing disease. There are several inherited disorders like hemochromatosis and Wilson disease that affect the liver. The common symptoms of diseases affecting the liver include swelling of the abdomen and legs, bruising easily, Jaundice, and change in color of stool and urine. Imaging tests and liver function tests can check liver damage and diagnose liver disease. Treatments given for liver diseases include anti-rejection drugs/immunosuppressants, chemotherapy drugs, targeted therapy, vaccines, anti-viral drugs, immunoglobulins, and corticosteroids.

Market Dynamics

Increasing prevalence of liver diseases, research and development of novel therapeutics, and approvals from regulatory bodies for liver disease treatment are attributed to the growth of the global liver diseases therapeutics market. For instance, on May 26, 2022, Pfizer Inc., U.S. based pharmaceutical company announced U.S. Food and Drug Administration granted fast-track designation to Pfizer's investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. Fast Track is a process designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and address unmet medical needs. The two drugs in combinational therapies are ervogastat and clesacostat. The decision was made based on Pfizer's nonclinical studies and phase 2a clinical study of drugs which showed reduced liver fat with favorable safety and tolerability profile.

Key features of the study:

This report provides an in-depth analysis of the global liver diseases therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global liver diseases therapeutics market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc..
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global liver diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liver diseases therapeutics market.

Detailed Segmentation:

Global Liver Diseases Therapeutics Market, Therapy Type:
- Anti-Rejection Drugs/Immunosuppressant
- Chemotherapy Drugs
- Targeted therapy
- Vaccines
- Anti-Viral Drugs
- Immunoglobulin's
- Corticosteroids
Global Liver Diseases Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Liver Diseases Therapeutics Market, By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Company Profiles
- Astellas Pharma Inc.
- Bristol-Myers Squibb
- Gilead Sciences
- Glaxosmithkline Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Takeda Pharmaceutical
- Valeant Pharmaceuticals
- Watson Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Alnylam Pharmaceuticals, Inc.
- Protagonist Therapeutics, Inc.
- Dicerna Pharmaceuticals, Inc.
- Endo International
- Provectus Biopharmaceuticals Inc.
- MAX BioPharma, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Therapy Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Liver Diseases Therapeutics Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Liver Diseases Therapeutics Market, By Therapy Type, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Anti-Rejection Drugs/Immunosupressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Chemotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Targeted therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Anti-Viral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Immunoglobulins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)

6. Global Liver Diseases Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)

7. Global Liver Diseases Therapeutics Market, By Region, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2018-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Glaxosmithkline Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi S.A
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Takeda Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Valeant Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Watson Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Theratechnologies Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Alnylam Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Protagonist Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Dicerna Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Endo International
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Provectus Biopharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
MAX BioPharma, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies